Disease · MONDO_0006311

myelodysplastic/myeloproliferative neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. myelodysplastic/myeloproliferative neoplasm. Diseases, record MONDO_0006311. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006311

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: myelodysplastic/myeloproliferative neoplasm; Open Targets
Open Targets ID: MONDO_0006311; Open Targets
Other names: MDS-MPD, MDS/MPN, MPD-MDS, myelodysplastic myeloproliferative cancer, myelodysplastic myeloproliferative disease, myelodysplastic/myeloproliferative diseases, myelodysplastic/myeloproliferative disorder, myelodysplastic/myeloproliferative disorders, myelodysplastic/myeloproliferative neoplasms, myeloproliferative/myelodysplastic disorders, myeloproliferative/myelodysplastic syndromes; Open Targets
Disease Ontology: DOID:4972; Disease Ontology
NCI Thesaurus: C27262; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 14 of its 27 drugs, from ClinicalTrials.gov; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZACITIDINE	CHEMBL1489	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
DECITABINE	CHEMBL1201129	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VENETOCLAX	CHEMBL3137309	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
ARSENIC TRIOXIDE	CHEMBL5483015	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CANAKINUMAB	CHEMBL1201834	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK2	Tyrosine-protein kinase JAK2	4	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	3	Tyrosine-protein kinase JAK1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3716	Drugs and targets
ACVR1	Activin receptor type-1	2	Activin receptor type-1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/90	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	2	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	2	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1788	Drugs and targets
ABL1	Tyrosine-protein kinase ABL1	1	Tyrosine-protein kinase ABL inhibitor	Phase 1	https://conductscience.org/library/genes/25	Drugs and targets
BCL2	Apoptosis regulator Bcl-2	1	Apoptosis regulator Bcl-2 inhibitor	Phase 2	https://conductscience.org/library/genes/596	Drugs and targets
BRD2	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 1/2	https://conductscience.org/library/genes/6046	Drugs and targets
BRD3	Bromodomain and extra-terminal motif (BET)	1	Bromodomain and extra-terminal motif (BET) inhibitor	Phase 1/2	https://conductscience.org/library/genes/8019	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01720225	Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk	Phase 2	113	2020-12-24	Leukemia	AZACITIDINE, DECITABINE	Its record names the disease	ClinicalTrials.gov
NCT03072043	Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms	Phase 1/2	55	2021-02-25	Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia	AZACITIDINE, EPRENETAPOPT	Its record names the disease	ClinicalTrials.gov
NCT02158858	A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies	Phase 1/2	336		Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis	PELABRESIB, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT06303193	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	Phase 1/2	160		Myelodysplastic Syndromes	PACRITINIB	Its record names the disease	ClinicalTrials.gov
NCT03613532	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Phase 1	102		Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant	AZACITIDINE, DECITABINE, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT04061421	Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)	Phase 1/2	94		MDS/MPN	CEDAZURIDINE, DECITABINE, ITACITINIB, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT02493530	TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea	Phase 1	60		Myelofibrosis, Polycythemia Vera	RUXOLITINIB, UMBRALISIB TOSYLATE	Its record names the disease	ClinicalTrials.gov
NCT05583175	Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies	Phase 2	50		Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation, Myeloid Malignancy	BUSULFAN, CYTARABINE, FLUDARABINE, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT04493138	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations	Phase 1/2	30		Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm	AZACITIDINE, QUIZARTINIB	Its record names the disease	ClinicalTrials.gov
NCT07549451	Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms	Phase 2	30		Phase II, Imetelstat, Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases	IMETELSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Decitabine vs Azacitidine: deaths from any cause	7 of 73	2 of 40	113	NCT01720225	Trial comparisons
Decitabine vs Azacitidine: serious adverse events	32 of 73	14 of 40	113	NCT01720225	Trial comparisons
Decitabine vs Azacitidine: Participants With a Response	49 of 70	19 of 39	109	NCT01720225	Trial comparisons
Decitabine vs Azacitidine: Number of Participants Who Became Transfusion Independent	12 of 37	3 of 19	56	NCT01720225	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42749863	DERIVED	1	PubMed
42617873	DERIVED	1	PubMed
41348911	DERIVED	1	PubMed
38744144	DERIVED	1	PubMed
38319837	DERIVED	1	PubMed
38259250	DERIVED	1	PubMed
37530627	DERIVED	1	PubMed
36881782	DERIVED	1	PubMed
33449813	DERIVED	1	PubMed
28774880	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006311

GET https://conductscience.org/api/diseases/v1/MONDO_0006311/drugs?page=2

API reference For AI assistants